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Cord bloodBackground: Bacille Calmette-Guérin (BCG), the live attenuated tuberculosis vaccine, is manufactured
under different conditions across the globe generating formulations that may differ in clinical efficacy.
Innate immune recognition of live BCG contributes to immunogenicity suggesting that differences in
BCG viability may contribute to divergent activity of licensed formulations.
Methods: We compared BCG-Denmark (DEN), -Japan (JPN), -India (IND), -Bulgaria (BUL) and -USA in vitro
with respect to a) viability as measured by colony-forming units (CFU), mycobacterial membrane integ-
rity, and RNA content, and b) cytokine/chemokine production in newborn cord and adult peripheral
blood.
Results: Upon culture, relative growth was BCG-USA > JPN  DEN > BUL = IND. BCG-IND and -BUL
demonstrated >1000-fold lower growth than BCG-JPN in 7H9 medium and >10-fold lower growth in
commercial Middlebrook 7H11 medium. BCG-IND demonstrated significantly decreased membrane
integrity, lower RNA content, and weaker IFN-c inducing activity in whole blood compared to other
BCGs. BCG-induced whole blood cytokines differed significantly by age, vaccine formulation and concen-
tration. BCG-induced cytokine production correlated with CFU, suggesting that mycobacterial viability
may contribute to BCG-induced immune responses.
Conclusions: Licensed BCG vaccines differ markedly in their content of viable mycobacteria possibly con-
tributing to formulation-dependent activation of innate and adaptive immunity and distinct protective
effects.
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Bacille Calmette-Guérin (BCG), the live attenuated vaccine
against tuberculosis (TB), is one of the world’s most widely used
vaccines [1] with billions of doses administered, including current
yearly administration of millions of doses at birth to protect new-
borns from disseminated forms of TB [2,3]. Epidemiological studies
have noted an unanticipated reduction in all-cause mortality in
BCG-vaccinated infants, especially in areas with high infectious
disease pressure, that cannot be solely explained by TB prevention,
supporting a protective heterologous effect of BCG vaccine [4,5].
Remarkably, there is great variability in the clinical benefits of
BCG immunization raising the possibility that differences in host
factors and/or vaccine formulations may influence BCG immuno-
genicity, efficacy and heterologous effects [6,7].
BCG is not a single entity, but rather a family of related live
attenuated vaccines propagated under distinct conditions across
the world resulting in BCG vaccine heterogeneity. Since its intro-
duction in 1921, BCG seed lots were distributed globally for vac-
cine production at multiple sites, generating distinct sub-strains
that differ by phenotype and genotype [12]. More than 14 BCG
strains are used globally with UNICEF being the largest supplier
[1]. Most countries import BCG from one of the international
WHO prequalified manufacturers, while few produce their own,
with lack of standardization in manufacturing conditions. More-
over, there are no standardized immunological correlates of pro-
tection for BCG’s effect against TB [8,9]. Parameters such as
presence and size of BCG scar and delayed-type hypersensitivity
do not predict protective efficacy against TB in humans [8,9].
BCG-induced scarring has been correlated with heterologous pro-
tective effects of BCG against a broad range of pathogens antigeni-
cally unrelated to TB [10,11]. Although potentially very important,
BCG vaccine variability is challenging to study, as a variety of vac-
cine formulations and vial batches are distributed by the Expanded
Program on Immunization (EPI) to qualified regions over time
[12,13]. A systematic review of randomized trials of BCG found
no evidence that its specific effect against TB was associated with
BCG strain [14]; however, this was an ecologic analysis prone to
confounding, only 2 of the 18 trials reported comparisons by strain,
none was in neonates, and none studied BCG-Russia or -Japan. It is
not currently known which BCG sub-strain/formulation offers the
best protection from TB disease or heterologous infections in
human populations [15]. Differences in BCG-induced innate
immune activation may contribute to distinct clinical effects of
BCG in populations of different ages [16].
Licensed BCG formulations may vary depending on (a) the orig-
inal seed strain, which may contain more than 1 genotype [17], (b)
mutations developing after a lab acquired the source strain and
before freeze-drying, (c) genotype predominance by different cul-
ture conditions [12], (d) epigenetic and structural differences due
to different culture/manufacturing conditions [12]. Before freeze-
dried seed lots were derived from a single spreading colony in
the 1960s, BCG was subcultured in different laboratories, yielding
minority subpopulations that can impact virulence [18], immuno-
genicity [19], viability [20], colony size/counts and heterologous
effects [21]. Despite the importance of BCG vaccines, growing evi-
dence of their variable protective effects [10,22], and recent evi-
dence that viability of BCG is key to its protective efficacy [23],
licensed BCG vaccine formulations have yet to be systematically
compared with respect to their viability and ability to activate
acute cytokine production that may shape immunogenicity [24].
Herein we compared five globally employed licensed BCG vac-
cine formulations in vitro with respect to viability and cytokine/
chemokine production in human cord and adult blood. Three of
the formulations studied are the most commonly used worldwide,and four of them are WHO prequalified (https://extranet.who.
int/gavi/PQ_Web/, last accessed May 24, 2019). Our work demon-
strates that licensed BCG vaccine formulations substantially differ
in mycobacterial viability that correlates with differences in cyto-
kine induction, raising the possibility that these differences may
contribute to their variable clinical effects.
2. Methods
2.1. BCG vaccine formulations
Five licensed freeze-dried BCG vaccine formulations were used
(Table 1) and are alluded to by country of manufacture: BCG-
Denmark-SSI (Statens Serum Institute, Denmark) (DEN), BCG-
Japan-JBL (Japan BCG laboratory) (JPN), BCG-Russia-SII (Serum
Institute of India, Pune, India) (IND), BCG-Russia-Bulbio (Bulbio,
NCIPD, Bulgaria) (BUL) and BCG-Tice-Merck (Tice strain, Merck,
USA) (USA). BCG Tice was obtained from the Boston Children’s
Hospital pharmacy, while the other formulations were shipped
under temperature controlled conditions to our laboratory and
stored at 2–8 C until use. Preservation of the cold chain was evi-
denced by intact vaccine vial monitors when present (BCG-IND).
Vaccines were reconstituted in their respective diluents per manu-
facturers’ instructions and used within 4–6 h. Based on availability,
2–6 lots from each formulation were tested and all vials used were
unexpired with the exception of few vials of BCG-DEN (due to ces-
sation of its production during the course of the study).
2.2. Bacterial viability stain/Assessment of mycobacterial membrane
integrity
Volumes of BCG vaccines estimated to carry 2x10^6 colony-
forming units (CFU, calculated based on vaccine label) were stained
immediately after reconstitution with 5 mM SYTO 9 and 30 mM
Propidium Iodide (PI) dyes in 1 mL of phosphate-buffered saline
(PBS), in accordance with the manufacturer’s protocol (LIVE/
DEAD BacLightTM Bacterial Viability Kit, Thermo Fisher, Waltham,
MA). Samples were incubated in the dark at room temperature
for 30 min, centrifuged at 12,000g, washed with PBS and fixed in
4% paraformaldehyde (PFA). Cell membrane integrity was assessed
by flow cytometry (LSR Fortessa, BD Biosciences).
2.3. Relative quantitation of bacterial RNA by flow cytometry
BCG volumes estimated to contain 2x10^6 CFU (calculated
based on vaccine label) were obtained from each BCG formulation
immediately after reconstitution. Samples were brought to a final
volume of 20 lL of PBS after centrifugation, and SYTO RNASelect
Green Fluorescent Cell Stain (Thermo Fisher) was added to a final
concentration of 250 lM. Samples were incubated at room tem-
perature in the dark for 30 min, then centrifuged, washed once
with PBS and fixed in 4% PFA. Mean fluorescence intensity of the
RNA dye was assessed by flow cytometry (LSR Fortessa, BD Bio-
sciences). The unstained controls were defined as being 1% RNA
positive and all events with equal or greater fluorescence were
gated as being ‘‘RNA positive”.
2.4. BCG culture in vitro
Actual CFU counts were obtained by the culturable microbial
count assay and used as a proxy for mycobacterial viability. Actual
CFU were compared to estimated CFU calculated based on informa-
tion on the vaccine inserts provided by the respective manufac-
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(Table 1). BCG vials were reconstituted to an estimated uniform
starting CFU concentration of 5x10^6 CFU/mL (according to
inserts), serially diluted 10-fold for 6 times in 7H9 broth, and pla-
ted in triplicate in casein-enriched (Sigma-Aldrich, St Louis, MO)
7H9 medium (e7H9), supplemented with oleic acid-albumin-
dextrose-catalase (OADC) enrichment (Difco Laboratories, Franklin
Lakes, NJ) per our laboratory’s protocol. Same BCG dilutions were
also tested on commercial Middlebrook 7H11 plates (M7H11,
Hardy Diagnostics, Santa Maria, CA) and Difco 7H11 medium (BD
Difco, Sparks, MD). BCG formulations were cultured under the
same laboratory conditions and colonies counted weekly for
6 weeks by 2 independent investigators each time. For each exper-
iment, CFU values at the time of maximum quantifiable growth
(20–300 colonies) for each formulation were adjusted for the
appropriate dilution factor, averaged (to provide the mean counted
CFU per vial for each formulation), and log-transformed to allow
statistical comparisons.
2.5. Human blood collection
In accordance with approved protocols from the Ethics Commit-
tee of the Beth Israel Deaconess Medical Center, Boston, MA (pro-
tocol number 2011P-000118) and The Brigham & Women’s
Hospital, Boston, MA (protocol number 2000-P-000117), de-
identified human cord blood samples were collected from healthy
full-term cesarean deliveries (>37 weeks gestational age). All de-
identified blood samples from healthy adult (age 18–40 years) par-
ticipants were collected with approval from the Ethics Committee
of Boston Children’s Hospital, Boston, MA (protocol number 307-
05-0223), after written informed consent. Blood samples were
anti-coagulated with 15 U/ml of pyrogen-free heparin sodium
(Sagent Pharmaceuticals, Schaumburg, IL, USA) and assayed within
4 h. Prior to study blood collection, none of the study participants
had ever received BCG.
2.6. Whole blood assay and cytokine/chemokine measurements
Whole blood assays were conducted as previously described
[25]. Briefly, whole blood diluted 1:1 in RPMI medium was stimu-
lated with different volume/volume (v/v) BCG concentrations in
96-well U-bottom plates. RPMI and LPS served as negative and pos-
itive controls, respectively. After 6 h and 18 h incubation at 37 C,
supernatants were collected and cryopreserved at 80 C until
assay. A fluorescent bead-based multianalyte xMAP technology
cytokine kit (Milliplex Human Cytokine/Chemokine Immunoassay,
Millipore Corp, Billerica, MA, USA) was employed to measure the
concentration of 41 cytokines/chemokines covering the spectrum
of Th1, Th2, Th17, chemoattractants and hematopoietic factors.
Assays employed a Luminex 200 Bioanalyzer (Luminex Corp, TX,
USA) set to acquire at least 50 events per cytokine.
2.7. Statistical analysis
Statistically significant differences in mycobacterial membrane
integrity, RNA content and CFU between formulations were
assessed by analysis of variance (ANOVA). BCG concentrations for
whole blood stimulations were calculated from vaccine inserts.
BCG-induced cytokine/chemokine responses were compared
across formulations by two approaches: (a) at equal calculated
CFU concentrations (1:10 dilution from BCG-DEN, -IND and -BUL
reconstituted vials; 1:100 dilution from -JPN reconstituted vials)
and (b) at equal v/v concentrations corresponding to the human
equivalent dose (1:10 dilution from BCG-DEN,-JPN,-IND,-BUL
reconstituted vials). Multiplex cytokine/chemokine data were ana-
lyzed using BeadView multiplex Data Analysis Software (v.1),
2232 A. Angelidou et al. / Vaccine 38 (2020) 2229–2240according to the manufacturer’s instructions (Millipore). Cytokine/
chemokine levels were normalized to RPMI control, log10-
transformed and represent log-fold-change over RPMI. To explore
trends in kinetic differences between newborns and adults, log-
transformed ratios of 6 h/18 h BCG-induced cytokine and chemo-
kine induction were calculated for all 41 cytokines/chemokines
measured, and aggregates compared by unpaired t-test. Statisti-
cally significant differences between age groups and across BCG
formulations were evaluated by ANOVA; BCG USA was not
included in Milliplex statistical comparisons across formulations
as it is distinct with respect to clinical indication (bladder cancer
rather than TB prevention), route of administration, and concentra-
tion (100x higher than the other formulations studied). Statistically
significant differences of absolute cytokine/chemokine levels were
evaluated by Kruskal-Wallis testing. A p-value < 0.05 was consid-
ered statistically significant. Statistical and graphical analysis was
performed using Prism 7 software (Graph Pad Software Inc, La Jolla,
CA, USA).
2.7.1. Data availability
The flow cytometry and cytokine/chemokine multiplex data
presented in this article are publicly available in the NIH ImmPort
database (https://immport.niaid.nih.gov/home) under accession
number SDY1596.Fig. 1. BCG formulations exhibit differences in mycobacterial cell membrane integrity a
average percentage of live cells as a proportion out of all events captured. N = 5 experim
an overlay of BCG cytometric analysis using SYTO RNA SelectTM Green Fluorescent Cell S
BCG USA was used as control. N = 4. Data are presented as mean +/ SD. Statistical sign
**p < 0.01, ***p < 0.01, ****p < 0.001. (For interpretation of the references to colour in th3. Results
BCG viability may be crucial for BCG protection [23]. To deter-
mine whether licensed BCG vaccine formulations may vary in their
content of live mycobacteria, we assessed the viability of BCG by
independent approaches, including mycobacterial membrane
integrity, RNA content and formation of CFU.
BCG formulations exhibited differences in mycobacterial cell
membrane integrity, as assessed by flow cytometry after staining
with cell permeable SYTO 9 dye and PI dye, which only enters
bacteria with damaged membranes [26]. BCG-IND demonstrated
a significantly lower percentage of intact mycobacterial cells
(65%) than -USA (88%), -BUL (97%), -JPN (97%) or -DEN (99%)
(Fig. 1A–B). As bacterial RNA contributes to sensing of viable bac-
teria by the innate immune system in vivo [27], we also compared
BCG vaccine formulations with respect to RNA content. An RNA-
selective stain demonstrated that BCG-IND vials contained only
54% RNA positive cells, significantly lower than -DEN (78%,
p = 0.047) and -USA (81%, p = 0.026) (Fig. 1C–D; proportions were
71.8% for -JPN, 74.6% for -BUL).
To assess culturable BCG colonies, we compared growth of
serial dilutions of BCG formulations plated in triplicate in e7H9,
commercial M7H11, and 7H11 agar prepared in our laboratory
(Supplemental Table 1). Upon culture of the BCG vaccine formula-nd RNA content as assessed by flow cytometry. (A) Representative dot-plot and (B)
ents testing at least 2 different lots of each BCG formulation. (C) Histogram showing
tain. (D) Bar graph showing the % of RNA + cells per equal number of CFU. Unstained
ificance denoted by one-way non-repeated measures ANOVA with Fisher’s LSD test.
is figure legend, the reader is referred to the web version of this article.)
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demonstrated significantly slower growth and fewer colonies com-
pared to the other formulations (Fig. 2A-B; Supplemental Fig. 1).
While BCG-JPN and -USA grew equally well in both e7H9 and
M7H11 and approached the anticipated CFU growth per vaccine
inserts, BCG-IND and -BUL demonstrated significant sensitivity to
media composition with >100-fold difference in CFU between
e7H9 and M7H11 media (Fig. 2C). Given the differences in compo-
sition of the media compared (Supplemental Table 1), we assessedFig. 2. Licensed BCG formulations differ markedly from one another in viability as me
dilutions of each BCG formulation were plated in (A) solid enriched 7H9 medium (e7H9)
counted weekly for 6 weeks. In both media types, BCG-IND and -BUL demonstrated sign
BCG-BUL viability (CFU) was >100-fold lower than anticipated per label. (C) Growth of B
medium. Mean CFU per ampule of each candidate was calculated from the average col
anticipated mycobacterial growth based on the vaccine label. Data are presented as mewhether presence of glycerol or malachite green in e7H9, or
absence of certain minerals (e.g., calcium chloride, zinc sulfate
and copper sulfate) in 7H11 may have a growth-favoring effect
for certain strains. Addition of glycerol to e7H9 resulted in non-
significant growth inhibition, while addition of malachite green
did not enhance BCG growth (Supplemental Fig. 2). Similarly,
7H11 medium containing the minerals mentioned above did not
impact BCG growth (Supplemental Fig. 2). The 7H11 medium con-
taining the same ingredients as M7H11 except for a different waterasured by colony forming units (CFU) in diverse culture media. Six serial 10-fold
and (B) commercial Middlebrook 7H11 medium (M7H11) in triplicate, and colonies
ificantly lower viability (CFU) compared to the other BCG formulations. Moreover,
CG-IND and -BUL was significantly lower (>100-fold) in e7H9 compared to M7H11
onies counted in independent experiments (N = 2–6) and also plotted against the
an +/ SD. Statistical comparisons with ANOVA. *p < 0.05, **p < 0.01, ***p < 0.01.
2234 A. Angelidou et al. / Vaccine 38 (2020) 2229–2240source, did not restore growth of BCG-IND or BCG-BUL (Fig. 2C),
raising the possibility that water composition used in different
facilities to make growth media may contribute to distinct growth
characteristics of BCG vaccine strains.
BCG viability is important for vaccine-induced immune
responses in vivo [28]. To assess whether differences in viability
were accompanied by differences in interaction with the immune
system, we investigated whether licensed BCG formulations dif-
fered with respect to induction of cytokines and chemokines by
newborn and adult blood leukocytes. Cytokine/chemokine secre-
tion patterns induced by BCG formulations in whole blood differed
significantly by age (Fig. 3A, Supplemental Table 2, Supplemental
Fig. 3). The 6 h/18 h log ratio was significantly higher in newborns
than adults for all formulations (Supplemental Table 2). For BCG-
DEN, -JPN and -IND, the mean newborn ratio was >0, while the
mean adult ratio was <0, suggesting a more rapid neonatal
response and kinetic differences in cytokine/chemokine produc-
tion by age. Production of IFN-c was delayed in both age groups
compared to other cytokines. BCG-IND induced the weakest IFN-
c responses compared to the other formulations, significantly so
in newborn cord blood (Fig. 3B). BCG-induced cytokine/chemokine
production in human whole blood was CFU concentration-
dependent (Supplemental Fig. 4). At concentrations reflecting
human equivalent doses, BCG-DEN and -JPN induced significantly
higher levels of hematopoietic factors (e.g., G-CSF, GM-CSF, PDGF
AB/BB) and Th1 cytokines (e.g. IL-1a, IL-1b, TNFa) compared to
BCG-IND and -BUL (Fig. 3C, Table 2). BCG-JPN induced sustained
elevations of IL-1a, IL-1b and TNFa at 18 h in cord blood, and a sig-
nificantly stronger IFN-c response compared to BCG-IND (Table 2).
However, when tested at equal CFU concentrations, BCG-JPN
demonstrated lower cytokine and hematopoietic factor induction
in whole blood than -DEN and -BUL, which induced significantly
higher log-fold changes in CCL7, G-CSF, GM-CSF and PDGF AB/BB
over the other formulations (Fig. 4A–B).
To assess whether there may be a relationship between viability
of BCG formulations and their cytokine-inducing activity, we con-
ducted a Spearman correlation analysis. Remarkably, viability of
licensed BCG formulations as measured by counted CFU correlated
positively with the magnitude of BCG-induced proinflammatory
cytokines and hematopoietic factors in whole blood, including IL-
1b, TNFa, IFN-c and G-CSF (Fig. 5), suggesting that the number of
viable organisms is the key trigger of the BCG-induced immune
response.4. Discussion
We report for the first time a systematic comparison of multiple
licensed BCG vaccine formulations with respect to viability and
cytokine induction in human cord and adult blood. We found that
licensed BCG vaccine formulations vary markedly in viable
mycobacteria (~10 to >1000-fold depending on growth medium)
in a manner that correlates with vaccine-induced cytokine and
chemokine secretion, raising the possibility that this variation
could contribute to reported variability in BCG’s clinical effects.
Viability was measured by multiple independent approaches
including live/dead staining, RNA content and culture, all of which
correlated with one another. Indeed, there is no standardized cul-
ture methodology recommended for BCG. For example, an interna-
tional collaborative study to evaluate and establish WHO reference
reagents for BCG vaccine, wherein each of the eleven participating
labs used their preferred culture media [29], demonstrated highly
variable CFU results, confirming that different production tech-
niques can have profound effects on BCG formulations.
Despite being cultured concurrently under standard laboratory
conditions, mycobacterial growth differed by medium used andBCG formulation. BCG-USA and -JPN had the most robust growth
in culture with counted colonies very closely matching the average
predicted CFU reported on the vaccine insert. Consistent with CFU
results, these formulations also had a very high percentage of
intact mycobacterial cells and RNA content. In contrast, BCG-IND
and -BUL, both derived from BCG Russia, grew more slowly and
demonstrated ~1–4 log-fold lower CFU per vial compared to their
label CFU (BCG-BUL p < 0.01; BCG-IND p = 0.07). Growth was par-
tially enhanced in commercial M7H11 medium. Discrepancies in
culture growth may indicate differences in viability after
lyophilization or reconstitution, or strain-dependent differences
in mycobacterial adaptation and/or micronutrient uptake [30].
Consideration should be given to the fact that our culture medium
ingredients are dissolved in distilled deionized (dd)H20, while
M7H11 is made with deionized water. In both cases, and especially
in the case of deionized water, the purity of the source water is
important, as differences in the mineral composition of water
may contribute to differences in BCG growth in vitro (personal
communication by Kaare Robert Haslov, SSI).
Slower growth has been associated with inocula that contain
fewer viable bacilli [31]. The number of live bacilli in the vaccine
product decreases with time [32], as does survival after freeze-
drying [33]. Accordingly, the slower growth observed by BCG-
IND and -BUL, despite equal calculated CFU concentrations, sug-
gests the presence of fewer viable bacilli at inoculum point com-
pared to other formulations. Interestingly, BCG-IND, which we
demonstrate had fewer culturable bacilli and induced weaker cyto-
kine responses, has been associated with lower frequency of BCG
scars [6,11,53], lower effectiveness against TB [34], and lack of
heterologous protection compared to BCG-DEN and -JPN [35]. Of
note, BCG-JPN known to be produced from younger cultures in
the logarithmic growth phase showed improved viability after
freeze-drying, and a superior immunizing potency in humans, as
suggested by the size of the tuberculin reaction and BCG scar,
and a positive correlation with tuberculin conversion rates, at least
in some studies [36].
We show here that BCG-IND contains fewer intact mycobacte-
ria, and together with BCG-BUL, contain less RNA-positive
mycobacteria compared to the other formulations. Presence of
RNA correlates with the ability of bacteria to activate immune
pathways involved in sensing viability in vivo [37], including via
signaling through Toll-like receptor (TLR)-8 which senses micro-
bial single stranded RNA (ssRNA) [27]. Indeed, live vaccines,
including BCG [38] trigger far more vigorous immune responses
than their killed counterparts, a response attributed to the ability
of the mammalian innate immune system to directly sense micro-
bial viability through detection of a special class of viability-
associated pathogen-associated molecular patterns (vita-PAMPs)
[28]. Innate immune recognition of livemycobacteria also activates
more CD8 + T cells than dead organisms [39]. As bacterial death is
associated with rapid loss of RNA, the low percentage of RNA pos-
itive cells likely signifies a lower content of live mycobacteria in
BCG-IND and -BUL. This marked variability in the quality (i.e., live
vs dead) of antigen across the different BCG formulations given to
different populations may have significant public health implica-
tions, as live BCG activates the immune systems distinctly from
dead BCG.
In addition to mycobacterial viability, the age of the human
study participants also played an important role in shaping cyto-
kine responses to BCG. BCG-induced whole blood cytokines/
chemokines were substantially increased at 6 h in newborns com-
pared to adults, whereas at 18 h the increases were greater in
adults. Overall, the robust magnitude and kinetics of cytokine/che-
mokine induction in newborn blood may reflect the relatively
higher concentrations of leukocytes, including monocytes, in
neonatal cord blood [40]. IFN-c was an exception to this pattern,
Fig. 3. (A) BCG-induced whole blood cytokine/chemokine pattern at 18 h differs significantly by age. Heat map depicts cytokines/chemokines after 18 h stimulation with
equal CFU concentrations of BCG, calculated from the vaccine inserts. Repeated-measures one-way ANOVA with Sidak’s post hoc test. N = 4–9 for newborn and 8–13 for adult
whole blood. (B) In NB, BCG-IND induced the weakest IFN-c responses compared to the other formulations. Box plots display medians and min-max values. Grey stars
indicate comparisons against RPMI control (Kruskal-Wallis test). (C) BCG-induced hematopoietic factors and cytokines at concentrations reflecting human equivalent
doses differ significantly by BCG formulation. Radar plots representing the BCG effect as a log-fold change over RPMI control. N = 6–10 for newborn and N = 7–11 for adult
whole blood. NB, newborn; AD, adult. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
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Table 2
At concentrations reflecting human equivalent doses, BCG-DEN and BCG-JPN induced significantly higher levels of hematopoietic factors and Th1 cytokines compared to BCG-IND and BCG-BUL.
6 h 18 h
Adjusted P value
Mean log difference (CI:95%)
Adjusted P value
Mean log difference (CI:95%)
BCG formulation
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0.8 (0.045;1.6)










IL-6 ns ns ns ns ns ns ns .0363
99 (0.045;1.9)
ns ns
IL-10 ns ns ns ns ns ns ns **0.0047
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Statistically significant log-differences by BCG formulation calculated by ANOVA with Tukey correction. BCG USA was analyzed separately as its clinical indication and ro of administration are different. N = 4–9 for NB; 5–11 for
AD.
* p < 0.05.
** p < 0.01.































Fig. 4. (A) BCG formulations tested at equal CFU concentrations differ in induction of cytokines/chemokines. Radar plots represent the BCG effect as a log-fold change
over RPMI control. (B) BCG-DEN induced significantly higher log-fold changes in CCL7, G-CSF, PDGF AB/BB, IL-1a and IL-1b compared to equal calculated CFU of the
other BCG formulations. ANOVA with Tukey correction. N = 6–9 for NB; 10–11 for AD. NB, newborn; AD, adult.
A. Angelidou et al. / Vaccine 38 (2020) 2229–2240 2237showing a delayed induction of secretion in both age groups. In
general, induction of Th1 immune responses, including IFN-c pro-
duction, is relatively low in newborns [41]. However, neonatalcytotoxic, c/d T cells, and NK cells can produce IFN-c in response
to certain stimuli, including BCG, in quantities that may be physi-
ologically sufficient to prime innate immune cells in vivo [42–44].
Fig. 5. BCG cytokine-inducing activity significantly correlates with BCG viability. (A) Spearman correlations between CFU–cytokines produced in NB after 18 h BCG
stimulation with concentrations reflecting human equivalent doses. (B) CFU-cytokine correlations for all cytokines/chemokines that were significantly changed over RPMI.
NB = newborn; AD = adult.
2238 A. Angelidou et al. / Vaccine 38 (2020) 2229–2240For both newborns and adults, BCG viability positively correlated
with vaccine-induced cytokine induction. Consistent with recent
observations [23], our findings suggest that mycobacterial viability
may contribute to robust cytokine responses important for the pro-
tective effects of BCG vaccines in humans.
Different BCG formulations induced distinct cytokine responses.
BCG-DEN and -JPN elicited robust production of CCL7, G-CSF, GM-
CSF, PDGF AB/BB, as well as IL-1a, IL-1b, TNFa, IL-6 and IL-10, com-
pared to BCG-IND and -BUL, whereas BCG-IND demonstrated the
weakest cytokine induction. Differences in cytokine and T cell
responses to different BCG vaccine formulations have also been
noted in vivo. For example, BCG-DEN or -Brazil preferentiallyinduced cytokines important for adaptive immunity (IL-12, IL-27,
IFN-c) from peripheral blood mononuclear cells, while vaccination
with BCG-JPN preferentially induced distinct pro-inflammatory
cytokines (IL-1a/b, IL-6, IL-24) [45]. Of note, in our study, absolute
levels of proinflammatory cytokines and hematopoietic factors in
whole blood, including IL-1b, TNFa, IFN-c, CCL7, G-CSF and GM-
CSF, correlated with the amount of culturable mycobacteria sup-
porting a role for BCG viability in immunogenicity. Each of these
cytokines has potential importance in responses to BCG: (a) pro-
duction of IL-1b, implicated in BCG-induced trained innate immu-
nity in low-resource settings, was highest for BCG-DEN, the
formulation most studied for beneficial heterologous effects in
A. Angelidou et al. / Vaccine 38 (2020) 2229–2240 2239early life [21,44,46,47]; (b) CCL7, a mycobacterial
lipoarabinomannan-inducible pleiotropic chemokine that induces
migration of leukocytes essential for the protective immune
response against mycobacteria [48]; (c) GM-CSF, a cytokine that
favors macrophage M1 polarization [49] and activates macro-
phages to limit intracellular growth of M. tuberculosis in vitro
[50]. Future studies should further assess the value of these cytoki-
nes as potential correlates of BCG-induced specific and heterolo-
gous protection. Lessons from comparing these BCG formulations
may also inform development of ‘‘BCG-like” adjuvanted vaccine
formulations conferring heterologous protection [51].
Low content of live bacteria and relatively lower induction of
key cytokines such as IL-1ß by BCG-BUL and, especially, BCG-IND
in vitro raises the possibility that these formulations may have
lower immunogenicity in vivo. This concern is based on: (a) unlike
live bacteria, and despite similar uptake by phagocytic leukocytes,
dead bacteria do not activate the inflammasome, key for produc-
tion of IL-1ß important for trained immunity [28,46]; and (b)
detection of live bacteria is mediated via TLR8 which is a receptor
for microbial ssRNA [27], hypermorphic alleles of which demon-
strate significantly enhanced BCG-mediated protection against
tuberculosis in humans in vivo, suggesting that recognition of live
BCG via TLR8 contributed to BCG protection [23]. Overall, to the
extent that our in vitro data are relevant to the action of these vac-
cines in vivo, our studies raise the possibility that BCG formulations
with low viability and cytokine induction may confer suboptimal
protection.
Our study features multiple strengths including (a) direct com-
parison of multiple batches and vials from diverse licensed BCG
vaccine formulations; (b) assessment of viability by three indepen-
dent approaches (mycobacterial membrane integrity, RNA content
and mycobacterial culture); and (c) modeling of age-specific cyto-
kine responses in vitro. Our study also has some important limita-
tions such as (a) being focused on in vitro data which may
incompletely reflect complex in vivo interactions; and (b) employ-
ing a U.S.-based cohort that may have distinct responses that are
not identical to BCG-induced responses in geographically diverse
populations [42], possibly due in part to the BCG immunization
status of mothers, among other factors [52].5. Conclusions
We report for the first time a systematic head-to-head compar-
ison of licensed BCG vaccine formulations which demonstrates
marked differences in viability that correlate with age-specific
induction of cytokines in vitro. As licensed BCG vaccine formula-
tions differ markedly in their clinical efficacy, the fresh insight pro-
vided by our study may inform future studies to define correlates
of protective immune responses and select optimal BCG vaccine
formulations for early life immunization. Our observations also
indicate that studies of new TB vaccines that are compared to
BCG should be interpreted cautiously with reference to a specific
BCG formulation and not presumed to generalize to all BCGs. Our
observations also indicate that studies of new TB vaccines that
are compared to BCG should be interpreted cautiously with refer-
ence to a specific BCG formulation and not presumed to generalize
to all BCGs. Overall, well-designed and appropriately powered clin-
ical studies directly comparing the specific and heterologous ben-
eficial effects of different BCG formulations are urgently needed to
inform best practice in BCG immunization.Funding
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